TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/01/2025
Back to search
Official data from USPTO
I-MAB BIOPHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
53
Latest update
12/04/2025
Trademark type
Combined
Nice classes
5, 42
Filing date
07/16/2019
Registration date
01/25/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/25/2022
Last transaction
12/04/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
04/13/2020
First use in commerce
04/28/2020
Drawing code
3
Owner type
03
Owner location
ROCKVILLE, MD
Examiner
RINGLE,JAMES W
Law office
M20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a blue and green stylized ring having a blue and dark blue left portion and a green and light green right portion. To the right of the ring is the word "I-MAB" written in dark blue upper case letters with a fading green arched cross-stroke extending from the left leg of the letter "A" through its center and extending through the center of the letter "B". Below the word "I-MAB" is the word "BIOPHARMA" written in dark blue upper case letters. The color white appearing in the mark represents transparent space and is not a part of the mark.
Holders and representatives
Holders
I-MAB BIOPHARMA US LIMITED
I-MAB BIOPHARMA CO., LTD
I-MAB
Representatives
Jacqueline Lesser Ice Miller LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Monoclonal antibodies for use in disease testing; biological preparations for the treatment of cancertumor suppressing agentsanti-cancer preparationspharmaceutical preparations for the treatment of immune system related diseases and disordersall comprising monoclonal antibodies
Class 42
Biomedical research services; conducting early evaluations in the field of new pharmaceuticals; quality control of goods and services; product quality testing; pharmaceutical product evaluation; biological research; conducting clinical trials for others that feature or contain monoclonal antibodies; research and development services in the field of antibodies
Publications
History of USPTO decisions and trademark events.
53 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/01/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/01/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/16/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/16/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/16/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/16/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/16/2025
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
12/25/2024
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
05/17/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
01/25/2022
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
12/24/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
12/23/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
12/23/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/23/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
12/23/2021
SNEA
SU-EXAMINER'S AMENDMENT WRITTEN
12/23/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
12/21/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
12/13/2021
IUAF
USE AMENDMENT FILED
11/12/2021
EISU
TEAS STATEMENT OF USE RECEIVED
11/12/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
11/02/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/07/2021
PUBO
PUBLISHED FOR OPPOSITION
09/07/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/18/2021
ALIE
ASSIGNED TO LIE
08/02/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/02/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/30/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/29/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/29/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/01/2021
GNRT
NON-FINAL ACTION E-MAILED
07/01/2021
CNRT
NON-FINAL ACTION WRITTEN
07/01/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/04/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/03/2021
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
06/03/2021
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
04/13/2021
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
10/13/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
04/09/2020
GNSL
LETTER OF SUSPENSION E-MAILED
04/09/2020
CNSL
SUSPENSION LETTER WRITTEN
04/09/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/11/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/10/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/10/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/24/2019
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/24/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/12/2019
GNRT
NON-FINAL ACTION E-MAILED
09/12/2019
CNRT
NON-FINAL ACTION WRITTEN
09/12/2019
DOCK
ASSIGNED TO EXAMINER
09/10/2019
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
07/24/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/23/2019
NWAP
NEW APPLICATION ENTERED
07/19/2019
Continuous trademark protection
Get notified about every new filing that threatens I-MAB BIOPHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.